TD Cowen Maintains BeiGene(BGNE.US) With Buy Rating, Maintains Target Price $254
TD Cowen Keeps Their Buy Rating on BeiGene (BGNE)
BeiGene Receives Positive CHMP Opinions for TEVIMBRA as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma
Nomura Adjusts BeiGene's Price Target to HK$174.91 From HK$158.37, Keeps at Buy
Nomura raised the target price of Beigene (BGNE.US) to $293.78, expecting a narrower loss in the third quarter.
Nomura released a research report, raising its revenue forecasts for BeiGene (BGNE.US) for the fiscal years 2024 and 2025 by 15.9% and 5.7%, respectively. This is mainly due to the bank's upward revision of sales forecasts for its drug Zanubrutinib. In addition, the bank also lowered its net loss forecasts for BeiGene for the fiscal years 2024 and 2025 by 45.2% and 44.2%, respectively. Nomura expects BeiGene's third-quarter revenue this year to reach $0.994 billion, a 2.7% increase year-on-year, a 7% increase quarter-on-quarter, 2% higher than market expectations; and expects a year-on-year increase in net losses for BeiGene last quarter.
US stock market outlook: Chinese assets collectively rise before the market! YINN surged more than 15%, bilibili rose more than 7%; Goldman Sachs: debt conversion is the first step in China's fiscal big move, which will stimulate economic growth.
Trump claimed to have received a 'plea for help' call from Cook, involving Apple being fined heavily by the European Union; Is there still an 'undercurrent' behind the bull market of US stocks? Goldman Sachs: The rise of the US dollar is a major threat; The gold price continues to hit new highs! As risk aversion heats up, spot gold rises above $2,700.